Showing 5251-5260 of 5644 results for "".
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Brits in the Dark Over Eye Health According to Orbis UKhttps://modernod.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/New research reveals that over half of Brits (53%) do not get their eyes tested every 2 years as recommended, and just over 1 in 10 (11%) can’t remember the last time they went to the optician. This is despite 45% of those surveyed listing sight as their most valuable sense. The surv
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b
- Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-initiates-phase-1b-clinical-trial-of-topical-ocular-formulation-of-akb-9778-for-primary-open-angle-glaucoma/2476645/Aerpio Pharmaceuticals dosing of the first subject in a phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The phase 1 study is a double-masked, multiple-ascending dose trial and will enroll four cohorts of 12 subj
- OcuSoft Introduces NEW OcuSoft Lid Scrub Allergy Eyelid Treatment for Red, Itchy Allergy Eyeshttps://modernod.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/OcuSoft announced the availability of new OcuSoft Lid Scrub Allergy Eyelid Cleanser for allergy conditions in convenient pre-moistened pads. OcuSoft Lid Scrub Allergy removes oil, debris, pollen and other contaminants from the eyelids while utilizing Green Tea Extract, Tea Tree Oil and PSG
- Our Tears Could One Day Tell Us If We Have Glaucomahttps://modernod.com/news/our-tears-could-one-day-tell-us-if-we-have-glaucoma/2476643/Contrary to what many think, high pressure inside the eye does not define glaucoma and investigators want to know if the proteins circulating in the fluid of our eyes might, according to researchers at the Medical College of Georgia at Augusta University. While some patients do have classi
- Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Millionhttps://modernod.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical ass
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Draper James and VSP Eyes of Hope Commit Nearly $4 Million to Fund Eye Care and Eyewear in Support of Young Womenhttps://modernod.com/news/draper-james-and-vsp-eyes-of-hope-commit-nearly-4-million-to-fund-eye-care-and-eyewear-in-support-of-young-women/2476637/More women than men are at risk for vision loss from eye diseases like glaucoma and macular degeneration. To help ensure more women have access to critical eye care, Draper James, the Southern-inspired lifestyle brand founded by Reese Witherspoon, announced a partne
- More Elderly Americans Dying From Fallshttps://modernod.com/news/more-elderly-americans-dying-from-falls/2476634/Death rates from falls are rising among elderly Americans and climbing fastest among seniors in their 90s, a US study suggests. Among all adults 75 and older, mortality from falls climbed 5.1% from 2000 to 2016, researchers report in JAMA. Death rates from falls rose the most—6.4%—among